Ménard S - Search Results

1

Radiation effects on development of HER2-positive breast carcinomas.

Castiglioni F, Terenziani M, Carcangiu ML, Miliano R, Aiello P, Bertola L, Triulzi T, Gasparini P, Camerini T, Sozzi G, Fossati-Bellani F, Ménard S, Tagliabue E. Castiglioni F, et al. Among authors: menard s. Clin Cancer Res. 2007 Jan 1;13(1):46-51. doi: 10.1158/1078-0432.CCR-06-1490. Clin Cancer Res. 2007. PMID: 17200337

2

HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors.

Ménard S, Balsari A, Casalini P, Tagliabue E, Campiglio M, Bufalino R, Cascinelli N. Ménard S, et al. Clin Cancer Res. 2002 Feb;8(2):520-5. Clin Cancer Res. 2002. PMID: 11839672

3

Role of HER2 in wound-induced breast carcinoma proliferation.

Tagliabue E, Agresti R, Carcangiu ML, Ghirelli C, Morelli D, Campiglio M, Martel M, Giovanazzi R, Greco M, Balsari A, Ménard S. Tagliabue E, et al. Among authors: menard s. Lancet. 2003 Aug 16;362(9383):527-33. doi: 10.1016/S0140-6736(03)14112-8. Lancet. 2003. PMID: 12932384

4

Linking survival of HER2-positive breast carcinoma patients with surgical invasiveness.

Tagliabue E, Agresti R, Casalini P, Mariani L, Carcangiu ML, Balsari A, Veronesi U, Ménard S. Tagliabue E, et al. Among authors: menard s. Eur J Cancer. 2006 May;42(8):1057-61. doi: 10.1016/j.ejca.2005.12.021. Epub 2006 Apr 18. Eur J Cancer. 2006. PMID: 16624551 Clinical Trial.

5

Fhit expression protects against HER2-driven breast tumor development: unraveling the molecular interconnections.

Bianchi F, Tagliabue E, Ménard S, Campiglio M. Bianchi F, et al. Among authors: menard s. Cell Cycle. 2007 Mar 15;6(6):643-6. doi: 10.4161/cc.6.6.4033. Epub 2007 Mar 20. Cell Cycle. 2007. PMID: 17374991 Free article. Review.

6

Regulation of breast cancer response to chemotherapy by fibulin-1.

Pupa SM, Giuffré S, Castiglioni F, Bertola L, Cantú M, Bongarzone I, Baldassari P, Mortarini R, Argraves WS, Anichini A, Menard S, Tagliabue E. Pupa SM, et al. Among authors: menard s. Cancer Res. 2007 May 1;67(9):4271-7. doi: 10.1158/0008-5472.CAN-06-4162. Cancer Res. 2007. PMID: 17483339

7

Protein kinase Calpha determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification.

Magnifico A, Albano L, Campaner S, Campiglio M, Pilotti S, Ménard S, Tagliabue E. Magnifico A, et al. Among authors: menard s. Cancer Res. 2007 Jun 1;67(11):5308-17. doi: 10.1158/0008-5472.CAN-06-3936. Cancer Res. 2007. PMID: 17545611

8

Two distinct local relapse subtypes in invasive breast cancer: effect on their prognostic impact.

Casalini P, Carcangiu ML, Tammi R, Auvinen P, Kosma VM, Valagussa P, Greco M, Balsari A, Ménard S, Tagliabue E. Casalini P, et al. Among authors: menard s. Clin Cancer Res. 2008 Jan 1;14(1):25-31. doi: 10.1158/1078-0432.CCR-07-0450. Clin Cancer Res. 2008. PMID: 18172248

9

FOXP3 expression and overall survival in breast cancer.

Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Mènard S, Tagliabue E, Balsari A. Merlo A, et al. Among authors: menard s. J Clin Oncol. 2009 Apr 10;27(11):1746-52. doi: 10.1200/JCO.2008.17.9036. Epub 2009 Mar 2. J Clin Oncol. 2009. PMID: 19255331

10

Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab.

Magnifico A, Albano L, Campaner S, Delia D, Castiglioni F, Gasparini P, Sozzi G, Fontanella E, Menard S, Tagliabue E. Magnifico A, et al. Among authors: menard s. Clin Cancer Res. 2009 Mar 15;15(6):2010-21. doi: 10.1158/1078-0432.CCR-08-1327. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276287

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

500 results

Search Page